Cystic Fibrosis Trial, Recruiting NCT04002882 Sponsor: Emory University Condition: Cystic Fibrosis
Back to Cystic Fibrosis

Cystic Fibrosis Trial, Recruiting

NCT04002882
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with cystic fibrosis (CF):

  • A confirmed CF diagnosis, based on a sweat test and/or genetic testing that shows two disease-causing mutations
  • Aged 16 years or older
  • Health has been stable, meaning no changes to medications or treatment for at least 21 days before the study visit
  • Enrolled in the Cystic Fibrosis Foundation (CFF) Patient Registry

For the longer-term part of the study (CF participants only):

  • CF participants whose blood sugar levels came back normal on the first glucose tolerance test done as part of this study

For healthy volunteers (people without CF):

  • Male or female, aged 16 years or older
  • Currently in good health, with no ongoing medical conditions

Who may not be able to join:

For people with CF:

  • Already diagnosed with CF-related diabetes (CFRD)
  • Currently receiving overnight tube feeding
  • Life expectancy of less than 6 months
  • Has had a lung transplant, or is currently on a waiting list for one
  • Has permanent metal implants in the body that are not safe for MRI scans
  • Unable or unwilling to take part in the main study tests — including a glucose tolerance test, a DEXA bone scan, and an MRI — due to claustrophobia, fear of blood draws, or other reasons
  • Currently pregnant or breastfeeding
  • The study visit falls within 1 to 8 weeks of starting a CFTR modulator medication
  • Currently taking ongoing oral corticosteroid (steroid) medication
  • The CF care team or study doctor has concerns about the person participating
  • Unable to give informed consent or assent

For healthy volunteers:

  • Diagnosed with cancer (other than localised skin basal cell cancer) within the past 5 years
  • Has a chronic illness, including respiratory conditions (such as asthma), diabetes or other hormone/gland disorders, autoimmune diseases, or other ongoing health conditions
  • Has HIV or another ongoing infection
  • Currently taking any medication for an ongoing or short-term illness (note: antidepressants and anti-anxiety medications are stated as acceptable)
  • Has had an acute illness within the past 3 weeks
  • Has taken antibiotics (oral or intravenous) or steroid tablets/medicines in the past 3 weeks
  • Unable or unwilling to complete the main study tests due to claustrophobia, fear of blood draws, or other reasons
  • Currently pregnant or breastfeeding
  • Unable to give informed consent or assent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jessica A Alvarez, PhD, RD, Emory University

Phone: 440-778-8373

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 July 2019
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Visceral Adipose Tissue volume (VAT) by Magnetic Resonance Imaging (MRI); Change in Disposition Index; Change in Forced Expiratory Volume in the first second (FEV1%)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov